The colonic epithelium is a continuously renewing tissue with a dynamic turnover of cells. Wnt pathway is a key regulator of its homeostasis and is altered in a large proportion of colon cancers. Protein kinase C (PKC) family of serine/threonine kinases are also involved in colon tumor formation and progression; however, the molecular role played by them in the Wnt pathway, is poorly understood. Reciprocal coimmunoprecipitation and immunofluorescence studies revealed that PKCz interacts with b-catenin mainly in tumoral colon cells, which overexpressed this PKC isoform. The pharmacological inhibition, the small interference RNA-mediated knockdown of PKCz or the expression of a dominant-negative form of it in tumoral SW480 cells, blocked in a dose-dependent manner the constitutive transcriptional activity mediated by b-catenin, the cell proliferation and the expression of the Wnt target gene c-myc. Remarkably, the PKCz stably depleted cells exhibited diminished tumorigenic activity in grafted mice. We show that PKCz functions in a mechanism that does not involve b-catenin degradation since the effects produced by PKCz inhibition were also obtained in the presence of proteosome inhibitor and in cells expressing a b-catenin degradationresistant mutant. It was found that PKCz activity regulates the nuclear localization of b-catenin since PKCz inhibition induces a rapid export of b-catenin from the nucleus to the cytoplasm in a Leptomycin B sensitive manner. Taken together, our results indicate that the atypical PKCz plays an important role in the positive regulation of canonical Wnt pathway.
The colonic epithelium is a continuously renewing tissue with a dynamic turnover of cells. Wnt pathway is a key regulator of its homeostasis and is altered in a large proportion of colon cancers. Protein kinase C (PKC) family of serine/threonine kinases are also involved in colon tumor formation and progression; however, the molecular role played by them in the Wnt pathway, is poorly understood. Reciprocal coimmunoprecipitation and immunofluorescence studies revealed that PKCz interacts with b-catenin mainly in tumoral colon cells, which overexpressed this PKC isoform. The pharmacological inhibition, the small interference RNA-mediated knockdown of PKCz or the expression of a dominant-negative form of it in tumoral SW480 cells, blocked in a dose-dependent manner the constitutive transcriptional activity mediated by b-catenin, the cell proliferation and the expression of the Wnt target gene c-myc. Remarkably, the PKCz stably depleted cells exhibited diminished tumorigenic activity in grafted mice. We show that PKCz functions in a mechanism that does not involve b-catenin degradation since the effects produced by PKCz inhibition were also obtained in the presence of proteosome inhibitor and in cells expressing a b-catenin degradationresistant mutant. It was found that PKCz activity regulates the nuclear localization of b-catenin since PKCz inhibition induces a rapid export of b-catenin from the nucleus to the cytoplasm in a Leptomycin B sensitive manner. Taken together, our results indicate that the atypical PKCz plays an important role in the positive regulation of canonical Wnt pathway.
Introduction
The intestinal epithelium follows the paradigms of stem cell biology established for other self-renewing tissues. Its unprecedented selfrenewal rate appears reflected in a high susceptibility to malignant transformation. Current evidence indicates that the Wnt cascade is the dominant force in controlling cell fate along the crypt-villus axis and colon cancer is actually considered as a disease of defective Wnt signaling (1) .
Canonical Wnt signals are transduced through Frizzled family receptors and LRP5/LRP6 coreceptor to the beta-catenin signaling cascade. Non-canonical Wnt signals are transduced through Frizzled family receptors and ROR2/RYK coreceptors to the Rho family guanosine triphosphatases, c-jun-NH 2 -terminal kinase or the Ca 2þ -dependent signaling cascades (2) . However, it has become clear that Wnt signals are context dependently transduced (3) . It has been established that Protein kinase C (PKC) is one of the key targets of noncanonical Wnt signaling, particularly in the Wnt/Ca 2þ pathway. In this respect, the phosphatidylinositol (PI) pathway and Ca 2þ levels are closely related to PKC activation. According to this, it has been reported that Xwnt5a and rat Frizzled2 activate the phosphatidylinositol pathway and increase the intracellular Ca 2þ levels in zebrafish embryos (4, 5) . In Xenopus embryos, overexpression of Frizzled causes the translocation of epitope-tagged PKCa from the cytoplasm to the plasma membrane (6,7) and Kuhl et al. (8) showed that PKC alpha phosphorylated disheveled in vitro. In addition, Kinoshita et al. (9) demonstrated that PKC delta is essential for Dsh function in a non-canonical Wnt pathway that regulates Xenopus convergent extension movements and that PKC delta regulates the function of Dsh in the Wnt/c-jun N-terminal kinase pathway. Nevertheless, there exist also evidence that PKC may be involved in canonical Wnt pathway regulation. In vitro, PKC has been shown to phosphorylate and inactivate glycogen synthase kinase (GSK) 3b (10) . An earlier report showed that a PKC inhibitor Ro31-8220 or chronic treatment with 12-O-tetradecanoyl phorbol 13-acetate resulted in complete block of Wnt-mediated inhibition of GSK3b in mouse 10T1/2 fibroblasts (11) . Others reported that treatment with the PKC inhibitors GF-109203X or Ro31-8220 caused b-catenin accumulation in certain human breast epithelial cell lines (12) . However, Hers et al. (13) showed that the PKC inhibitors GF-109203X and Ro31-8220 also inhibit GSK3b, potentially slowing down b-catenin degradation. Thus, although much evidence suggests that PKC is involved in the Wnt signaling pathway, the molecular roles played by PKC isoforms in this pathway are not well understood because most of the evidence has been obtained using PKC inhibitors that are also potent GSK3b inhibitors.
On the other hand, PKC isozymes have long been implicated in carcinogenesis. Altered PKC activity, localization and/or expression has been observed in virtually all tumor types examined and classification of PKC isozyme-specific functions in transformed cells is emerging (14) . The importance of PKCs in colon cancer has been demonstrated and several lines of evidence indicate that colon carcinogenesis is accompanied by changes in PKC isozyme expression, including a dramatic increase in the level of PKCbII expression (15, 16) .
The PKC family of serine/threonine kinases is subdivided into three subfamilies: the classical, novel and atypical PKCs (cPKC, nPKC and aPKC, respectively) based on differences in sequence homology and cofactor requirements. Classical PKCs are activated by Ca 2þ and diacylglycerol (DAG); nPKCs are activated by DAG but not by Ca 2þ , and aPKCs are not activated by these molecules (17) but can be regulated by 3-phosphoinositides (18) , by phosphorylation mediated by phosphoinositide-dependent kinase PDK1 (19, 20) and through specific protein-protein interactions (21, 22) . Atypical PKCs have been implicated in establishment of cell polarity, cell proliferation and cell survival (22) (23) (24) (25) . In this work, we demonstrate that the atypical PKCf modulates in a positive manner canonical Wnt signaling by controlling nuclear b-catenin localization.
Plasmids
The pTOPFlash and pFOPFlash reporter plasmids were obtained from Upstate Biotechnology. Plasmids encoding dominant-negative PKCf (Flag.PKCzeta.K/W, Addgene plasmid 10800, Cambridge, MA) (26) and b-catenin degradation-resistant mutant (pcDNA3-S33Y beta-catenin, Addgene plasmid 19286) (27) were obtained from Addgene, a non-profit organization dedicated to making it easier for scientists to share plasmids. Plasmid-encoding human b-catenin (CTNNB1) was obtained from OriGene, Rockville, MD (catalog No. SC107921). For knockdown PKCf experiments, we used the pSUPER.PKCzeta.RNAi plasmid donated by Dr Alex Toker to Addgene (Addgene plasmid 10803) whose construction and effectiveness are described in (28) .
Cell culture RKO (human colon carcinoma), HT-29 or SW480 (human colorectal adenocarcinoma) malignant cells and non-malignant IEC-18 (rat epithelial intestinal cells) and 112CoN (human colon) cells were all obtained from the American Type Culture Collection (Manassas, VA). RKO and 112CoN cells were maintained in Dulbecco's Modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), antibiotics (120 mg/ml penicillin and 200 mg/ml streptomycin) and 2 mM L-glutamine. IEC-18 cells were cultured in the same medium but supplemented with 5% FBS, antibiotics, L-glutamine, 4.5 g/l glucose and 0.1 U/ml insulin. HT-29 cells were mantained in McKoy medium supplemented with 10% FBS, antibiotics and 2 mM glutamine. SW480 cells were maintained in Dulbecco's Modified Eagle's medium F-12 supplemented with 5% FBS, antibiotics and 2 mM glutamine. All cells were cultured in a humidified 5% CO 2 incubator at 37°C.
Transfection and luciferase reporter gene assay Transfection was carried out with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Briefly, cells were seeded in 24-well plates at 3.5 Â 10 5 cells per well. Twenty-four hours after seeding, cells were placed in a serum-free medium and transiently transfected with 0.7 lg of reporter plasmid (pTOPFlash) or control plasmid (pFOPFlash) plus 0.05 lg of pRL luciferase plasmid (transfection control). Luciferase reporter activity was measured 24 h after transfection in cell lysates using the Dual luciferase assay kit (Promega, Madison, WI). The activity was normalized with respect the activity of Renilla luciferase or with the protein content in each sample. To express a dominant-negative form of PKCf (K/W), cells were transiently transfected with 0.5-2 lg of plasmid Flag.PKCzeta.K/W obtained from Addgene (ID10800) using Lipofectamine 2000.
Incubation with Wnt3a ligand and pharmacological inhibition of PKCf
For the pharmacological PKCf inhibition in SW480 cells, 24 h posttransfection with the pTOPFlash or pFOPFlash plasmids, cells were incubated in the absence or presence of the myristoylated PKCf-selective inhibitor (10-100 lM) for 1 h. Then, cells were washed, homogenized and luciferase activity was measured. In the case of RKO cell line, transfected cells were serum starved (2% instead of 10%) for 10 h and treated with Wnt3a (100 ng/ml; Chemicon) for a total 12 h period. During the last hour, cells were also incubated in the absence or presence of myristoylated PKCf-selective inhibitor (10-100 lM). Cells were washed, homogenized and luciferase activity was measured.
PKCf knockdown
In the cases of transient silencing of PKCf, cells were transfected with pSuperPKCzRNAi plasmid (constructed and probed by Dr Alex Toker, as described in ref. 29) or with control plasmid obtained from Addgene (ID 10803) using Lipofectamine 2000. In some experiments, cells were also transiently cotransfected with the pTOPFlash or pFOPFlash plasmids and with increasing amounts of pSuper.PKCz.RNAi plasmid maintaining constant the total amount of transfected DNA (2 lg) by adding pSuper plasmid control.
To generate stable transfections, SW480 cells were transfected with either 1 lg of control pSuper plasmid or cotransfected with 900 ng of pSuperPKCzRNAi plus 100 ng of pSUPERpuro plasmids. Stable transfectants were selected with 3 lg/ml puromycin (Sigma) for 4 weeks, and clones were picked and screened for PKCf silencing by flow cytometry.
Western blotting
Samples of protein (100 lg) were separated by 10 or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by electrophoretic transfer to nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% non-fat dry milk and incubated overnight at 4°C with the corresponding primary antibody. Detection was achieved using the Supersignal kit (Pierce, Rockford, IL) with a horseradish peroxidase-conjugated second antibody. An actin antibody was used as control for equal loading.
Immunofluorescence analysis RKO or IEC-18 cells were grown on coverslips. Cells were washed with phosphate-buffered saline (PBS), fixed in ice-cold acetone for 5 min, washed in PBS and blocked with 1% IgG-free bovine serum albumin for 1 h. The cells were incubated overnight at 4°C with the corresponding primary antibodies in blocking solution, washed three times with PBS and incubated for 1 h in darkness at room temperature with secondary antibodies [fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit and TRITC-conjugated goat antimouse]. After washing, the coverslips were mounted with the antifade reagent Vectashield. The fluorescence of cells was examined using a confocal microscope (Leica TCS SP5) with a krypton argon laser.
3-(4,5-Dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide assay SW480 cells were grown in 24-well plates at 1.2 Â 10 5 cells per well for 24 h. Then, 20 lM of the PKCf-selective inhibitor was added to the medium and the incubation period continued for 24 h. Cells were incubated with 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT; 0.5 mg/ml final concentration) for additional 3 h at 37°C. Reaction was stopped adding 1 ml of acid isopropanol to each well. Formazan salts were dissolved and quantified spectrophotometrically at 570 nm.
Reverse transcription-polymerase chain reaction Total RNA was isolated from cells 48 h after transfection using Trizol reagent (Life Technologies, Carlsbad, CA). Total RNA was reverse transcribed using SuperScript One-Step reverse transcription-polymerase chain reaction with Platinum Taq (Invitrogen) using the following gene-specific primers: human c-myc forward: 5#-TACCCTCTCAACGACAGCAG-3#; human c-myc reverse: 5#-TCTTGACATTCTCCTCGGTG-3#. GAPDH was reverse transcribed under the same conditions to be used as control, with the following primers: forward 5#-CATCTCTGCCCCCTCTGCTGA-3#; reverse 5#-GGAT-GACCTTGCCCACAGCCT-3#.
Immunoprecipitation
Confluent cells were washed and homogenized in ice-cold lysis buffer containing 20 mM Tris-HCl pH 7.5, 10 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 2 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100 and a mixture of protease inhibitors and protein phosphatase inhibitors. Aliquots of cell extracts (1 mg/ml) were incubated overnight with 1 lg/ml of primary antibody at 4°C with gentle shaking. Then, 20 ll protein A-sepharose (30%) were added and incubation continued for 2 h. Immune complexes were then washed three times with buffer A (50 mM Tris-HCl, 0.6 M NaCl, 1% Triton X-100, 0.5% Non-idet P-40, pH 8.3) supplemented with 0.1 mg/ml trypsin inhibitor and 1 mM phenylmethylsulfonyl fluoride and once with buffer B (20 mM TrisHCl pH 7.5, 0.15 M NaCl) containing protease and phosphatase inhibitors.
Quantification of nuclear b-catenin by FACS analysis
Nuclei were purified from 1 Â 10 6 cell samples using a Nuclei Isolation Kit (Sigma-Aldrich, St. Louis, MO) according to manufacturer's instructions. Nuclei were washed with staining buffer and fixed with ice-cold 4% paraformaldehyde in PBS. Then they were permeabilized with ice-cold 0.1% Triton X-100 in PBS during 10 min and centrifuged to remove the supernatat. Nuclei were blocked in staining buffer and then labeled with anti-human b-catenin antibody at 1:50 dilution in staining buffer followed by goat anti-mouse-FITC secondary antibody at 1:100 dilution in staining buffer. As negative control, nuclei maintained in separate tubes were treated in parallel with FITC-labeled mouse IgG1 antibody and with FITC-labeled secondary antibody. After final wash, nuclei were fixed with ice-cold PBS containing 2% paraformaldehyde and analyzed by flow cytometry using a FACScalibur apparatus (Becton Dickinson, Franklin Lakes, NY). To analyze, independent gates were generated for intact cells (R1) or isolated nuclei staining with propidium iodide (R2) before flow cytometry analysis.
Xenograft tumor model
Stably transfected SW480 cells with control pSUPER plasmid (thus expressing endogenous wild-type PKCf) or with pSuperPKCzRNAi (PKCf knockdown) were collected by trypsinization. Then, 7.5 Â 10 5 cells per injection site were resuspended in high concentration Matrigel (BD Biosciences, Franklin Lakes, NY), diluted in PBS to 50% final concentration and subcutaneously injected into the flanks of 8-week-old CD1 nude mice. Each mouse was injected at two sites at the right flank with control cells and at the left flank with knockdown PKCf cells. Three weeks after inoculation, animals were euthanized and tumors were removed and weighted. Statistical analysis Data are expressed as mean ± standard error of the mean (SEM). Statistical analysis of the data was performed by the Student's t-test. A value of P ,0.05 was considered statistically significant.
Results
PKCf and b-catenin coimmunoprecipitate in a reciprocal manner and colocalize in malignant cells It has been reported that colon tumoral cell lines exhibit marked changes in PKC isoform expression pattern compared with normal L.B.Luna-Ulloa et al.
(non-malignant) cells (14) . Whereas some PKC isoforms such as a, d and bI are downregulated in malignant cells, others, like atypical PKCf, are upregulated in these cells in comparison with non-malignant ones as shown in Figure 1A . Since atypical PKCf has been involved in establishment of cell polarity, cell proliferation and cell survival in many cellular systems (30), we hypothesized that it may interact with Wnt key canonical proteins. In order to investigate this, b-catenin was immunoprecipitated from normal 112CoN and from malignant RKO or SW480 cell extracts and the immunoprecipitates analyzed by western blot. As it can be observed in Figure 1B , PKCf coimmunoprecipitated in a reciprocal manner with b-catenin mainly from malignant cells. The interaction is specific since PKCd, which is also expressed in these cells, did not coimmunoprecipitated with b-catenin as shown in the Figure 1B . Consistent with these results, immunofluorescence assays followed by confocal microscopy analysis presented in Figure 1C , showed a clear colocalization of b-catenin with PKCf in malignant cells at the cytoplasm and in some regions of the nucleus, but not in non-malignant 112CoN or IEC-18 cells in which b-catenin (red) appeared located at the plasma membrane, whereas PKCf (green) localized at the cytoplasm.
PKCf-selective inhibitor blocked b-catenin-mediated transcriptional activity in both RKO and SW480 colon carcinoma cell lines In order to examine the effect of PKCf inhibition on canonical Wnt signaling, we employed the b-catenin transcriptional activity reporter system TOPFlash/FOPFlash. We have used RKO human malignant cells that have normal canonical Wnt signaling (express wild-type APC protein) and are responsive to ligand in comparison with SW480 human malignant cells that express a truncated version of APC and have constitutively active Wnt signaling. The specificity of the selective PKCf myristoylated pseudosubstrate inhibitor was examined by in vitro activity assays and the dose required to effectively inhibit PKCf (data not shown). Twenty-four hours posttransfection with the pTOPFlash or pFOPFlash plasmids, RKO malignant cells were incubated in the absence or presence of Wnt3a (100 ng/ml) for 12 h and during the last hour, both SW480 and RKO cells were PKCz in tumoral colon cell lines also incubated in the absence or presence of the PKCf-specific inhibitor (20 lM). As it can be observed in Figure 2A , PKCf inhibition substantially decreased the constitutive b-catenin-mediated transcriptional activity in SW480 cells and also the Wnt3a-induced b-catenin transcriptional activity in RKO cells. When the pTOPFlash or pFOPFlash-transfected SW480 cells were incubated in the absence or presence of increasing amounts of the PKCf inhibitor, the transcriptional activity mediated by b-catenin was blocked in a dose-dependent manner, as it can be observed in Figure 2B . Taken together, these results suggest that PKCf modulates in a positive way the canonical Wnt pathway.
PKCf knockdown or expression of a dominant-negative (kinase dead) PKCf decreases dose dependently the b-catenin-mediated transcriptional activity In order to confirm that the observed effects were mediated by PKCf inhibition, we used an RNAi approach to transiently block the PKCf expression. It is important to mention that plasmids used have been constructed and successfully probed previously by Dr Alex Toker (28) who donated the plasmids to Addgene from which we obtained them (see Materials and Methods). As we show in Figure 3A , a great reduction in PKCf protein level was observed 36 h after transfection with 2 lg small interference RNA plasmid in comparison with plasmid control. Maintaining invariable the total amount of DNA transfected, we tested increasing small interference RNA-PKCf plasmid concentrations (0, 1 or 2 lg) to determine whether the effects on b-catenin reporter transcriptional activity in SW480 cells were dose dependent. Results presented in Figure 3A clearly showed that the reporter activity decreased as siRNA-PKCf was increased. These results confirmed that the effects observed on canonical Wnt signaling are mediated by the atypical PKCf and reinforce the notion about the positive role played by this PKC isozyme in Wnt pathway. We next asked if the catalytic activity of PKCf was needed to mediate the positive effects on b-catenin-mediated actions. To express a dominant-negative form of PKCf (K/W), SW480 cells were transiently cotransfected with void plasmid or with 1 or 2 lg of FlagPKCf K/W plasmid and with the TOPFlash/FOPFlash reporter. After 24 or 36 h posttransfection, the reporter activity was examined, as shown in Figure 3B . The level of expression of endogenous and kinase dead PKCf is shown at the right of the Figure 3 . It can also be seen that b-catenin reporter transcriptional activity was negative affected in a dose-dependent way in a similar manner at both 24 or 36 h posttransfection, thus indicating that the effects observed are mediated by the catalytic activity of PKCf.
PKCf inhibition blocks SW480 cell proliferation and diminishes the expression of the Wnt target gene c-myc Since canonical Wnt signaling activation promotes cell proliferation via the expression of target genes such as c-myc and cyclin D1, we hypothesized that PKCf inhibition in SW480 cells might reduce the expression of c-myc and the cell proliferation. To test this, SW480 cells were incubated 24 h in the absence or presence of 20 lM PKCf myristoylated pseudosubstrate inhibitor. After this time, MTT was added to the medium for 3 h and proliferation assayed. As it can be seen in Figure 4 panel A, the PKCf inhibitor blocked .50% the cell proliferation in comparison with control (vehicle treated) cells. We also examined the effect of PKCf inhibition on the key Wnt target gene c-myc expression. Figure 4B shows that the expression of c-myc both at the level of protein (left) and at the level of messenger RNA (right) were decreased as result of PKCf inhibition, in comparison with control (vehicle treated) cells.
PKCf silencing affects the tumorigenic activity of engrafted SW480 cells In order to determine the effect of small interference RNA-mediated knockdown of PKCf in tumorigenic activity of SW480 cells, we made use of a xenograft model in immunocompromised mice. Stably transfected SW480 cells with control pSUPER plasmid or with pSuperPKCzRNAi were obtained as described under Materials and Methods and selected by FACS analysis. As shown in Figure 4C , stable transfectants exhibiting .90% decreased expression of PKCf were obtained. These cells were isolated, grown and subcutaneously injected into the left flanks of immunocompromised nude mice. In the same animals, control cells stably transfected with pSuper control plasmid and thus expressing wild-type PKCf were subcutaneously injected into the right flanks of each animal. After 3 weeks, mice were killed by cervical dislocation and tumors were removed and weighted. Notably, all mice produced little tumors from control cells ( Figure 4C bottom, right flanks, 28 mg average weight) at the time of killing, whereas knockdown cells injected in the same animals did not form (A) A myristoylated PKCf pseudosubstrate inhibitor blocks both constitutive and Wnt3a-induced b-catenin transcriptional activity. SW480 or RKO cells were cotransfected with pRL and the TOPFlash or FOPFlash reporter plasmids. Twenty-four hours posttransfection, RKO cells were serum starved (2%) for 10 h and then Wnt3a (100 ng/ml) was added to the medium to stimulate cells for 12 h period. During the last hour, cells were also incubated in the absence or presence of 20 lM myristoylated PKCf inhibitor. In the case of SW480 cells, 24 h posttransfection cells were incubated in the absence or presence of the inhibitor for 1 h. After incubation with or without the inhibitor, cells were washed, lysed and luciferase activity was assayed. The activity was normalized with respect the activity of Renilla luciferase or with respect the protein content in each sample. The results represent the means ± SEM of at least three independent experiments. ÃÃ p , 0.01, (B) PKCf inhibitor blocks in a dose-dependent manner, the transcriptional activity mediated by b-catenin. Twenty-four hours posttransfection of SW480 cells with the pTOPFlash plasmid, cells were incubated in the absence or presence of the myristoylated PKCf-selective inhibitor (10-100 lM) for 1 h. Then, cells were washed, homogenized and luciferase activity was measured and normalized with respect to the total protein content in the cell lysate. The results represent the means ± SEM of at least three independent experiments. L.B.Luna-Ulloa et al. Figure 4C left flank, bottom). There was only one animal that produced tumors from both control and knockdown cells (photograph in Figure 4C , top) but even in this case, the weight of the tumor produced by knockdown cells was the half of that produced from control cells. Therefore, these results clearly indicated that PKCfdepleted cells exhibit a diminished tumorigenic activity in grafted mice indicating an important role for PKCf in tumor growth in vivo.
tumors (see
PKCf inhibition modulates canonical Wnt activation without altering b-catenin expression levels but regulating b-catenin localization Because the stability and localization of b-catenin are the main important mechanisms by which its actions are tightly regulated, we investigated the effects of PKCf inhibition on these parameters. To this end, SW480 cells were incubated 30, 45 min or 1 h in the absence or presence of 20 lM PKCf myristoylated pseudosubstrate inhibitor. After indicated times, cytoplasmic and nuclear fractions were obtained from the cell extracts and the presence of b-catenin analyzed in each fraction by western blot. Interestingly, we have found that there was no detectable degradation of b-catenin protein levels in cell extracts of SW480 cells obtained from treated cells (1 h) in comparison with control untreated ones as it can be observed in Figure 5A (top). However, in spite the total amount of b-catenin was unchanged, its localization was changed as result of PKCf inhibition: whereas cytoplasmic b-catenin levels increased, nuclear b-catenin levels were simultaneously decreased. Notably, the fast time-course observed to promote exit of b-catenin from the nucleus ( Figure 5A down) was compatible with the rapid negative effect seen on transcriptional activity after only 1 h treatment of cells with the PKCf inhibitor as shown in Figure 2A .
To confirm that PKCf does not affect b-catenin levels, RKO cells were cotransfected with reporter plasmid TOPFlash and with a plasmid-encoding wild-type b-catenin or encoding a b-catenin degradation-resistant mutant (S33Y). As expected, b-catenin transcriptional activity increased as result of overexpression of wild-type or mutant b-catenin in RKO cells ( Figure 5B ). When the cells were incubated in the absence or presence of PKCf inhibitor, a blockade of b-catenin transcriptional activity was induced as result of PKCf inhibition in the same proportion both in b-catenin wild-type-expressing cells as in b-catenin degradation-resistant mutant expressing cells ( Figure 5B ). In addition, the effect of preincubation with the proteasome inhibitor MG-132 was examined. The optimal concentration and incubation time were determined in RKO cells, which do not have constitutively active canonical Wnt pathway. As shown in Figure 5C , treatment of Figure 5C ). These data suggested therefore that PKCf activity does not affect b-catenin protein levels but instead is needed to regulate b-catenin localization. In order to investigate this, immunofluorescence assays were performed to visualize the localization of b-catenin in SW480 cells incubated during 1 h in the absence or presence of PKCf inhibitor (20 lM). Figure 2B ) indicated that it was .50%, as shown in Figure 6B . When the cells were preincubated with the exportin 1 (CRM-1) inhibitor Leptomycin B, the b-catenin exit induced by PKCf inhibition was completely blocked ( Figure 6A ). Taken together, data indicated that PKCf activity is needed to maintain b-catenin at the cell nuclei in order to activate canonical Wnt signaling.
Discussion
Although it is well known that Wnt and PKC signaling pathways are both involved in the colon carcinogenesis process and tumor progression, their synergistic contribution to these processes or crosstalk between them has just recently been approached (6, (8) (9) (10) . PKC is one of the key targets of non-canonical Wnt signaling, particularly in the Wnt/Ca 2þ pathway. However, there also exist evidence that indicates that PKC may be involved in canonical Wnt pathway regulation. In this respect, whereas the interaction of PKCf with elements of canonical Wnt signaling such as GSK3b had been described previously (10, 17) , the interaction between atypical PKCf and b-catenin had not been reported before. Here, we provide evidence that atypical PKCf selectively interacts with b-catenin and that PKCf modulates in a positive way the canonical Wnt pathway. The atypical PKCs (aPKC) differ from other PKCs in that their catalytic activity is not dependent upon diacylglycerol, calcium or phosphatidylserine. This functional divergence is due to a unique N-terminal regulatory domain on aPKCs that lacks calcium-, phospholipid-and diacylglycerol-binding motifs. The activity of this type of PKC isozymes can be regulated by 3-phosphoinositides, phosphorylation by the phosphoinositide-dependent kinase PDK1 and through specific protein-protein interactions (22) . We have found here that the mechanism by which PKCf seems to modulate Wnt pathway is through regulating the nuclear localization of b-catenin instead of regulating its stability (Figures 5 and 6 ). The nuclear localization control provides a very rapid and efficient mechanism to block Wnt target gene expression. Consistent with this, we have found that the treatment for only 1 h with PKCf inhibitor induced a severe blockade of the robust b-catenin-mediated transcriptional activity exhibited by SW480 cancer cells.
Nuclear b-catenin is the hallmark of activated canonical Wnt signaling. Thus, nuclear import/export of b-catenin represents a crucial step in regulating signaling competent b-catenin levels and serves as an attractive target for pharmacological interventions in cancer and other diseases associated with altered Wnt signaling. The conservation of nuclear shuttling activity in cancer may be important for cell survival or growth. b-Catenin contains no recognizable nuclear localization signal, so it has been proposed that it is imported by a Piggyback mechanism. However, it has been demonstrated that b-catenin nuclear import can occur in the absence of transport factors such as importins or the Ran GTPase (31) . Moreover, b-catenin was found to compete with importin-b for docking to components of the nuclear pore complex. Indeed, the central arm repeats are required for b-catenin import, and these are structurally related to the importin-b HEAT repeats that bind the nuclear pore complex (32) .
With respect to the b-catenin nuclear export, although the precise mechanism is not completely understood, to date, several distinct b-catenin nuclear export pathways have been reported. For example, APC and Axin, besides their function in the destruction complex, have been shown to shuttle between the nucleus and the cytoplasm and facilitate nuclear export of b-catenin by CRM-1-dependent pathway (33, 34) . On the other hand, there is also experimental evidence that b-catenin can directly bind to CRM-1 through its central armadillo (ARM) repeats region independently of APC to exit the nucleus (35) . In addition, it was reported that treatment with Leptomycin B, a specific inhibitor of CRM-1-mediated nuclear export, causes a dramatic retention of nuclear b-catenin induced by leukocyte enhancer factor-1 (36) . Consistent with this, we showed here that a CRM-1-mediated pathway is involved in PKCf induction export of b-catenin. It has been also reported that b-catenin can exit the nucleus independently of the CRM-1 exporter and RanGTP (35, 37) and that the RanBP3 export factor enhances nuclear export of active b-catenin in a CRM-1-independent manner (37). Takemaru et al. (38) have reported that Chiby (Cby) co-operates with 14-3-3 adapter proteins to facilitate nuclear export of b-catenin, following phosphorylation of Cby by Akt kinase. The APC-and Axin-directed nuclear export pathways may be coupled with proteasomal degradation of b-catenin. However, the outcomes of the Cby-and RanBP3-dependent export are currently unknown. All these experimental evidence suggest therefore that cells may have two or three different nuclear export mechanisms for b-catenin. In addition, how these nuclear export routes operate co-ordinately and differentially to fine-tune nuclear b-catenin levels remains largely elusive.
PKCf may be at the crossroad of cell proliferation regulation by Wnt and PI3K signaling pathways It is well known that aPKCs are implicated in establishment of cell polarity, cell proliferation and cell survival (19, 22) . Interestingly, Wnt signaling has been shown to interact with PKCf signaling to promote cell polarization and cell proliferation. With respect to regulation of cell polarization, Zhang et al. (39) found that as result of Wnt5a treatment, Dvl forms a complex with PAR3, PAR6 and with PKCf resulting in stabilization and activation of PKCf to promote axon differentiation in cultured hippocampal neurons. Likewise, Wolf et al. (40) demonstrated that aPKCf is required for Wnt-mediated attraction of commissural axons and proper anterior-posterior axon guidance.
The role played by aPKCs in cell proliferation is well known. Indeed, many of the proteins reported to interact with PKCf have been involved in the maintenance of the proliferative state in the cell, including those that regulate AP-1, nuclear factor-kappaB and the mitogen-activated protein kinase cascades linked to Ras signaling. In addition, it has been reported that the atypical PKC iota, closely related with PKCf, is a human oncogene that participates in multiple aspects of the transformed phenotype of human cancer cells (41) . Consistent with this, we showed here that the proliferative state of the SW480 colon cancer cells was decreased when we inhibited the activity of PKCf ( Figure 4A ).
The major activation pathway of PKCf depends on phosphatidylinositol-3,4,5-trisphosphate (PIP3), which is mainly produced as result of phosphatidylinositol-3 kinase (PI3K) activation induced by growth factors. 3-PI-dependent protein kinase 1 (PDK1), which binds with high affinity to PIP3, phosphorylates and activates PKCf. PI3Ks can be activated by both receptor tyrosine kinases and G-protein-coupled receptors such as Frizzleds. Whereas activating Wnt pathway mutants are found in the majority of colon cancers, mutational activation of the PI3K is also common in colorectal carcinomas: K-Ras or B-Raf mutation occurred in 79% of cell lines and 59% of human colorectal carcinomas (42) . Because GSK3b is a key component of both pathways, it is widely assumed that active PI3K signaling feeds positively into the Wnt pathway by PKB-mediated inhibition of GSK3b. However, examinations of the crosstalk between these two signaling pathways have led to a great debate. On one hand, stimulation by insulin and growth factors in colon cell lines have been proposed to act by PKB-mediated inhibition of GSK3b. On the other hand, it was reported that the effect of insulin was blocked by PI3K inhibition, but only partially attenuated by inhibition of PKB (43), indicating the existence of both PKB-dependent and -independent mechanisms.
Another issue to take into account with respect to PI3K and Wnt signaling crosstalk is the recent findings supporting a model wherein APC loss alone stabilizes the levels of cytoplasmic b-catenin but is insufficient for stimulating nuclear accumulation of b-catenin and intestinal cell proliferation (44) . Rather, the nuclear accumulation of b-catenin and attendant proliferation require the activities of K-Ras, Raf1 and Rac1, suggesting a previously unappreciated molecular link between growth factor signaling and APC loss.
Our data suggest a model in which PKCf would be the focal point of crosstalk between Wnt-b-catenin and PI3K pathways. In this model, it can be speculated that growth factors present in cell culture media or Wnt agonists, activate PKCf, which in turn feeds positively into the Wnt pathway by PKCf-mediated phosphorylation of either b-catenin or another protein(s) that control b-catenin nuclear localization (retention) and/or facilitates its interaction with T cell factor/ coactivators complex, resulting in Wnt gene transcription activation. We are currently addressing this model. 
